Saxol Showcases Its Innovation at Prestigious Oncology Event
Saxol is proud to announce its selection among ten groundbreaking startups in the fields of biotech, medtech, and digital health that are pioneering innovations in oncology. These companies have been chosen to present their projects to a distinguished audience of oncologists, investors, potential partners, and a panel of industry experts.
This prestigious event provides a unique platform for emerging companies to gain significant visibility, showcase their technological advancements, and engage in valuable discussions that could shape the future of cancer treatment. By fostering collaboration between startups and key players in the oncology ecosystem, the event aims to accelerate the development and adoption of transformative solutions.
Represented by Ph. Bordeau, Saxol had the honor of presenting its latest innovation in the fight against chemotherapy-induced peripheral neuropathy (CIPN). This condition, a common and debilitating side effect of cancer treatments, affects millions of patients worldwide, significantly impacting their quality of life. Saxol’s solution offers a novel approach to mitigating these effects, contributing to a more patient-centered and effective oncology care pathway.
By participating in this event, Saxol reaffirms its commitment to advancing oncology research and improving patient outcomes. We extend our gratitude to the organizers and the expert panel for this remarkable opportunity to share our vision and engage with the broader medical and scientific community.
Watch the recording of Ph. Bordeau’s presentation at OncoStart Summit 2024.
